Literature DB >> 7815494

Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation.

C M Shih1, C M Chen, S Y Chen, Y H Lee.   

Abstract

We previously demonstrated that the core protein of hepatitis C virus (HCV) can suppress gene expression and replication of hepatitis B virus (HBV) in a human hepatoma cell line (HuH-7). In this study, we have characterized the phosphorylation property of HCV core protein and examined the effect of phosphorylation on its suppressive activity of HBV. Our results indicated that both the full-length HCV core protein (22 kDa) and its processed or degraded forms (14 to 18 kDa) were phosphorylated in insect cells. As demonstrated by using the glutathione S-transferase fusion protein expression system and in vitro transcription and translation system, the phosphorylation of HCV core protein was carried out by protein kinase A (PKA) and protein kinase C (PKC) in vitro. In both kinase reactions, it was determined that the phosphorylated amino acid was a serine residue. The potential phosphorylated sites in core protein were identified as residues Ser-53 and Ser-116 for PKA and Ser-53 and Ser-99 for PKC. Comparison of the phosphorylation intensities of the wild type and Ser mutants suggested that Ser-99 and Ser-116 were the major phosphorylation sites for PKC and PKA, respectively. The phosphorylation of Ser-99 and Ser-116, but not Ser-53, in HCV core protein was essential for the suppressive activity of HCV core protein on HBV gene expression and replication in HuH-7 cells. Mutation of the former two serine residues to alanine or aspartate residues led to a drastic loss of the inhibitory effects of HCV core protein on HBV gene expression (both transcription and antigen production) and pregenomic RNA encapsidation, as well as the release of HBV virus particles. In contrast, the Ser-53 mutant conferred the same level of suppressive activity as the wild type did. This property is in accordance with the observation that Ser-99 and Ser-116 are the predominant phosphorylation sites in the HCV core construct. All serine mutants (including those with mutations in PKA, PKC, and both kinase recognition sites) of HCV core protein retained the ability to translocate into the nucleus. Furthermore, wild-type HCV core protein diminished its suppressive activity when cells were treated with PKA or PKC inhibitor. In conclusion, HCV core protein is a phospho-protein and in HuH-7 cells, its trans suppression of HBV gene expression and replication is positively regulated by PKA and PKC. The role of phosphorylation in the control of trans-suppressive activity cannot be reproduced by introducing an acidic residue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815494      PMCID: PMC188689     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Phosphorylation of specific serine residues within the acidic domain of the phosphoprotein of vesicular stomatitis virus regulates transcription in vitro.

Authors:  A M Takacs; S Barik; T Das; A K Banerjee
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Modulation of the dimerization of a transcriptional antiterminator protein by phosphorylation.

Authors:  O Amster-Choder; A Wright
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

3.  Phosphorylation of the phosphatase modulator subunit (inhibitor-2) by casein kinase-1. Identification of the phosphorylation sites.

Authors:  P Agostinis; O Marin; P James; P Hendrix; W Merlevede; J R Vandenheede; L A Pinna
Journal:  FEBS Lett       Date:  1992-06-29       Impact factor: 4.124

Review 4.  The regulation of transcription by phosphorylation.

Authors:  T Hunter; M Karin
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

5.  Functional motifs of delta antigen essential for RNA binding and replication of hepatitis delta virus.

Authors:  M F Chang; C Y Sun; C J Chen; S C Chang
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway.

Authors:  A S Kekulé; U Lauer; L Weiss; B Luber; P H Hofschneider
Journal:  Nature       Date:  1993-02-25       Impact factor: 49.962

7.  Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome.

Authors:  M J Selby; Q L Choo; K Berger; G Kuo; E Glazer; M Eckart; C Lee; D Chien; C Kuo; M Houghton
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

8.  Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.

Authors:  A Grakoui; D W McCourt; C Wychowski; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome.

Authors:  R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  45 in total

1.  Interaction between hepatitis C virus core protein and translin protein--a possible molecular mechanism for hepatocellular carcinoma and lymphoma caused by hepatitis C virus.

Authors:  Ke Li; Lin Wang; Jun Cheng; Yin-Ying Lu; Ling-Xin Zhang; Jin-Song Mu; Yuan Hong; Yan Liu; Hui-Juan Duan; Gang Wang; Li Li; Ju-Mei Chen
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

2.  Membrane binding properties and terminal residues of the mature hepatitis C virus capsid protein in insect cells.

Authors:  Tomoaki Ogino; Hiroyuki Fukuda; Shinobu Imajoh-Ohmi; Michinori Kohara; Akio Nomoto
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  C-terminal nsP1a protein of human astrovirus colocalizes with the endoplasmic reticulum and viral RNA.

Authors:  Susana Guix; Santiago Caballero; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection.

Authors:  E Rodríguez-Iñigo; J Bartolomé; N Ortiz-Movilla; C Platero; J M López-Alcorocho; M Pardo; I Castillo; V Carreño
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 6.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 7.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 8.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

9.  Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1.

Authors:  H Aoki; J Hayashi; M Moriyama; Y Arakawa; O Hino
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

10.  Phosphorylation of the porcine reproductive and respiratory syndrome virus nucleocapsid protein.

Authors:  Sarah K Wootton; Raymond R R Rowland; Dongwan Yoo
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.